Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: Apixaban for Postoperative VTE Prophylaxis in IBD
NCT03935451Phase 1Recruiting
- Sponsor
- McMaster University
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in venous thromboembolism (VTE) comparing Apixaban with Placebo (2 arms). Primary endpoints: Incidence of post operative venous thromboembolism events (DVT/PE) at 3 months and Incidence of bleeding while undergoing treatment with oral anticoagulant or placebo at 3 months. Started Sep 2021; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03935451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935451.